Hypertensive patients are often associated with multiple risk factors, such as dyslipidemia, abnormal glucose metabolism, and obesity. A large number of epidemiological studies have confirmed that hypertensive patients are often combined with dyslipidemia and interact with each other, thus further increasing the risk of cardiovascular disease. Studies have shown that 90% of patients with persistently elevated blood lipids and total cholesterol higher than 300 mg/L can develop coronary heart disease; a 1 mmol/L increase in total cholesterol increases ischemic stroke by 25%. Lipids are the lipids in plasma, and the main harm of dyslipidemia is that lipids are deposited in the wall of blood vessels and atherosclerosis occurs. There are now more than 120 million hypertensive patients in China, half of whom have dyslipidemia. In turn, about half of the people with dyslipidemia have hypertension, hypertension combined with dyslipidemia often occurs in obese patients, and with the further expansion of the obese population, the number of this part of the patient will further increase. Clinical lipid tests include total cholesterol, triacylglycerol, low-density lipoprotein cholesterol (Ldl-C) and high-density lipoprotein cholesterol (HDL-C). Since dyslipidemia is asymptomatic and must be detected by blood tests, hypertensive patients with normal lipids are advised to have their lipids tested at least once a year. Early detection of dyslipidemia and intervention is important and can lead to the reversal of atherosclerotic plaques. LDL-C is a cholesterol-rich lipoprotein, which is a major risk factor for the development of atherosclerosis. For the treatment of patients with hypertension combined with dyslipidemia, LDL-C should be taken as the primary lowering target. For those who cannot achieve the lipid-lowering goal with dietary control and exercise, they should be treated with drugs. Statin drugs are the main drugs for lipid-regulating therapy, which can reduce total cholesterol, triacylglycerol, and LDL-C. Research data show that simple antihypertensive therapy can reduce the risk of coronary heart disease by 16%, and the risk of stroke by 39%, and that if lipid-regulating therapy is added on top of this, it can reduce the risk of coronary heart disease by 36%, and the risk of stroke by 27%. It is clear that the benefits can only be maximized with concomitant treatment.